Vaccine Research Center

History

The origins of the Vaccine Research Center date back to 1996 following discussions between President Bill Clinton and NIAID Director Dr. Anthony Fauci regarding research addressing HIV/AIDS. Recognizing the potential impact a vaccine could make in decreasing the global public health burden of HIV, President Clinton in 1997 announced a plan to establish an HIV vaccine research center on the NIH campus. The dedication ceremony for the VRC took place in 1999 with President Clinton delivering the opening remarks.

Named in honor of immunization advocates former Governor of Arkansas Dale Bumpers and his wife Betty Flanagan Bumpers, the Vaccine Research Center opened its doors as Building 40 on the NIH campus in 2000. The founding investigators leading the new center came from a range of scientific disciplines including virology, immunology, structural biology, bioengineering, manufacturing, clinical research and regulatory science. While HIV vaccine research and development remains a core focus, the scope of activities has expanded to include advancing scientific understanding and developing biologics for a broad array of infectious pathogens.

Leadership

Director

Deputy Director

Organization

The VRC is composed of an Office of the Director, basic research laboratories and major programs.

Office of the Director:

• Management and Operations
• Scientific Partnerships and Collaborations
• Strategic Planning

Laboratories:

• Immunology Laboratory

  • Cellular Immunology Section
  • Flow Cytometry Core
  • The Genome Analysis Core
  • Human Immunology Section
  • Immunology Section
  • ImmunoTechnology Section
  • Integrative Bioinformatics of Immune Systems Core
  • Nonhuman Primate Immunogenicity Core
  • Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology (PREMISE)
  • Tissue Analysis Core
  • Virus Persistence and Dynamics Section

• Virology Laboratory

  • Humoral Immunology Core
  • Humoral Immunology Section
  • Structural Bioinformatics Core
  • Structural Biology Section
  • Virology Core

• Viral Pathogenesis Laboratory

  • Biodefense Research Section
  • Molecular ImmunoEngineering Section
  • Translational Science Core
  • Yeast Engineering Technology and Immunobiology Core

Programs:

• Clinical Trials Program
• Regulatory Science and Strategy Program
• Translational Research Program
• Vaccine Immunology Program
• Vaccine Production Program

Research Areas

To advance scientific understanding of infectious pathogens and develop investigational biologics, the VRC maintains programs in the following:

Key scientific areas**:**

• Disease acquisition and viral pathogenesis
• Infection and vaccine-induced immune responses
• Structure-based vaccine design
• Structural basis for antibody-mediated virus neutralization
• Vaccine antigens, antibody platforms, and routes of delivery

Primary disease-specific programs:

• Alphaviruses (Chikungunya, Western/Eastern/Venezuelan Equine Encephalitis)
• Coronaviruses (SARS, MERS, SARS-CoV-2)
• Enterovirus D68
• Filoviruses (Ebola and Marburg)
• HIV/AIDS
• Influenza
• Malaria
• Nipah Virus
• Paramyxoviruses (Parainfluenza Virus and Human Metapneumovirus)
• Respiratory Syncytial Virus
• Tuberculosis
• Zika Virus

Projects

HIV

In July 2010, a collaboration between the National Institute of Allergy and Infectious Diseases and officials at the Vaccine Research Center found that two human HIV antibodies, named VRC01 and VRC03, could potentially be used against a wide range of types and mutations of HIV in the design of a preventive HIV vaccine for human use, as well as in the formation of better antiretroviral therapy drug cocktails. The discovery, a potentially landmark one in the drive to find a vaccine for AIDS should it be validated and further improved.

Ebola

In 2016 research efforts led by Nancy Sullivan at Vaccine Research Center and J. J. Muyembe-Tamfum from the Institut National de Recherche Biomedicale (INRB) in the Democratic Republic of Congo resulted in the discovery of a monoclonal antibody, mAb114, from a survivor from the 1995 Kikwit outbreak of Ebola virus disease. mAb114 is a monoclonal antibody therapy that is being evaluated as a treatment for Ebola virus disease and has shown great success by lowering the mortality rate from 70% to about 34% in the 2018-2020 Kivu Ebola Virus Outbreak. In August 2019, Congolese health authorities, the World Health Organization, and the U.S. National Institutes of Health promoted the use of mAb114, alongside a similar Regeneron-produced treatment, over other treatments yielding higher mortality rates, after ending clinical trials during the outbreak.

Image Gallery

| President Clinton at Vaccine Research Center Cornerstone Dedication Ceremony -- | File:017-BushW02032003a_72dpi.jpg | President George W. Bush visits the Vaccine Research Center | File:President_Obama_visits_the_Vaccine_Research_Center.jpg | President Barack Obama visits the Vaccine Research Center | File:President_Donald_Trump_Visits_NIH_(49749996863).jpg | President Donald Trump visits the Vaccine Research Center | File:P20210211AS-1401_-_50970923622.jpg | President Joseph Biden visits the Vaccine Research Center

References

1. "Vaccine Research Center Mission and History {{!}} NIH: National Institute of Allergy and Infectious Diseases".
2. "Vaccine Research Center Brochure".
3. (March 16, 2020). "To Develop Coronavirus Treatment, Lilly Taps AbCellera Antibody Platform". GEN: [[Genetic Engineering & Biotechnology News]].
4. "Commencement Address at Morgan State University in Baltimore, Maryland {{!}} The American Presidency Project".
5. "Dale and Betty Bumpers Vaccine Research Center".
6. "Building 40, Vaccine Research Center".
7. Malakoff, David. (1999-03-10). "Nabel to Head AIDS Vaccine Institute". [[Science (journal).
8. McManus, Rich. (May 18, 1999). "Intramural HIV Vaccine Work Moves Forward". The NIH Record.
9. McManus, Rich. (June 1, 1999). "Nabel Outlines Plans for Vaccine Center". The NIH Record.
10. Levin, Jennifer. (November 15, 2012). "Sanofi Appoints Dr. Gary J. Nabel as Chief Scientific Officer". Fierce Biotech.
11. (October 17, 2013). "NIAID selects new director of the Vaccine Research Center".
12. (March 16, 2022). "Director of NIAID's Vaccine Research Center Announces Retirement | NIAID: National Institute of Allergy and Infectious Diseases".
13. Fauci, Anthony S.. (February 16, 2022). "Leadership Transition at the NIAID Vaccine Research Center". NIAID.
14. (April 25, 2023). "NIAID Appoints Ted Pierson as New Vaccine Research Center Director". NIAID.
15. (September 5, 2000). "Mascola Named VRC Deputy Director". The NIH Record.
16. "Organizational Chart". NIAID.
17. "Vaccine Research Center (VRC) Contacts". NIAID.
18. "Vaccine Research Center (VRC) Contacts". NIAID.
19. "Vaccine Research Center (VRC) Contacts". NIAID.
20. "Vaccine Research Center (VRC) Contacts". NIAID.
21. "Vaccine Research Center (VRC) Contacts". NIAID.
22. "Vaccine Research Center (VRC) Contacts". NIAID.
23. "Vaccine Research Center Senior Leadership". NIAID.
24. "Vaccine Research Center Senior Leadership". NIAID.
25. "Vaccine Research Center Senior Leadership". NIAID.
26. (October 29, 2021). "VRC’s Graham Retires After More Than 20 Years". The NIH Record.
27. "Vaccine Research Center Senior Leadership". NIAID.
28. "Immunology Laboratory {{!}} NIH: National Institute of Allergy and Infectious Diseases".
29. "Virology Laboratory {{!}} NIH: National Institute of Allergy and Infectious Diseases".
30. "Viral Pathogenesis Laboratory {{!}} NIH: National Institute of Allergy and Infectious Diseases".
31. "Lesia Dropulic, M.D. {{!}} NIH: National Institute of Allergy and Infectious Diseases".
32. "Ruth Woodward DVM {{!}} NIH: National Institute of Allergy and Infectious Diseases".
33. "Adrian McDermott, M.Sc., Ph.D. {{!}} NIH: National Institute of Allergy and Infectious Diseases".
34. (March 2016). "Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody". Science.
35. Hayden, Erika Check. (2016-02-26). "Ebola survivor's blood holds promise of new treatment". Nature.
36. McNeil, Donald G.. (12 August 2019). "A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo". The New York Times.
37. Molteni, Megan. (12 August 2019). "Ebola is Now Curable. Here's How The New Treatments Work".